Keyword: Boehringer Ingelheim
New real-world data from Lilly and BI show their SGLT2 med Jardiance topped GLP-1s at preventing heart failure hospitalization.
With a strong sales quarter for its lung disease med Ofev in the books, Boehringer Ingelheim hopes to tackle another rare lung disease.
Biocon's manufacturing problems cost it and Mylan again; CStone's CEO racks up nearly $20 million in 2018 pay; Novartis sells Suzhou plant.
Boehringer inked a string of pipeline-boosting deals this year while racking up big sales gains. Now, it's rejigging its executive team.
BI's new ad campaign for Stiolto Respimat centers on “inhaleability," a word it created to highlight its slow-moving mist delivery method.
Boehringer Ingelheim Eli Lilly’s Jardiance is going after an indication in chronic heart failure—and the FDA just sped up the process.
Boehringer Ingelheim has invested €225 million on inhaler production with a new plant in Spain and expanded lines in Germany.
If you'd popped into ADA, you might have thought you’d wandered into a kidney disease or NASH meeting. And that has drugmakers excited.
Lilly and Boehringer have already shown that Tradjenta doesn’t hurt patients’ hearts. But the pair is back with even more supporting evidence.
Boehringer and Lilly's new video series teams a cardiologist host, a dog and a guest physician to raise awareness of diabetes-related heart disease.
